Allergan stock falls after depression study fails
Allergan PLC shares declined in after-hours trading Wednesday after the pharmaceutical giant announced that a major study of one of its candidates on major depressive disorder did not produce the desired results. Allergan said that three studies of rapastinel showed that the drug did not produce different results from a placebo, and an interim analysis showed that primary and key secondary goals would not be met. "We are deeply disappointed with these results, and they are a vivid reminder that drug development is extremely challenging... Читать дальше...